Inactive Instrument

Tetraphase Pharmaceuticals, Inc.

US88165N2045

Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

March 12, 2020 at 06:13 am EDT

Tetraphase Pharmaceuticals, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced total revenue was USD 7.376 million compared to USD 18.904 million a year ago. Operating loss was USD 67.532 million compared to USD 73.281 million a year ago. Net loss was USD 70.085 million compared to USD 72.158 million a year ago. Basic loss per share was USD 22.85 compared to USD 27.48 a year ago.

Latest news about Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc. Enters into A Termination of Lease and Voluntary Surrender of Premises Agreement	20-12-18	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-13	CI
La Jolla Pharmaceutical Completes Merger with Tetraphase Pharmaceuticals	20-07-31	CI
Tetraphase Pharmaceuticals, Inc. Announces Executive Changes	20-07-29	CI
Tetraphase Pharmaceuticals, Inc. Announces Resignation of Larry Edwards as CEO	20-07-29	CI
Tetraphase Pharmaceuticals, Inc. Announces Appointment of Michael Hearne as Chief Financial Officer	20-07-29	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from S&P TMI Index	20-07-29	CI
La Jolla Pharmaceutical Company completed the acquisition of Tetraphase Pharmaceuticals, Inc..	20-07-27	CI
Armistice Capital Enters into Support Agreement with La Jolla Pharmaceutical	20-06-30	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Value Index	20-06-26	CI
Tetraphase Pharmaceuticals, Inc.(NasdaqGS:TTPH) dropped from Russell Microcap Index	20-06-26	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-23	CI
La Jolla Pharmaceutical Sends Letter to Tetraphase Pharmaceuticals	20-06-22	CI
United States Food and Drug Administration Approves XERAVA of Tetraphase Pharmaceuticals, Inc	20-06-05	CI
AcelRx Pharmaceuticals, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-03	CI
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	20-05-14	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
La Jolla Pharmaceutical Company made a non-binding proposal to acquire Tetraphase Pharmaceuticals, Inc. for $14.6 million.	20-05-05	CI
AcelRx Pharmaceuticals, Inc. definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. for $10.4 million.	20-03-15	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-12	CI
Tetraphase Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	20-03-11	CI
Tetraphase Pharmaceuticals, Inc. announced that it has received $9.997939 million in funding from Armistice Capital LLC	20-01-27	CI
Tetraphase Pharmaceuticals, Inc. Announces Director Appointments	20-01-23	CI
Tetraphase Pharmaceuticals, Inc. announced that it expects to receive $9.997939 million in funding from Armistice Capital LLC	20-01-21	CI
Tetraphase Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI

Chart Tetraphase Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals